Across TCGA pan-cancer cohorts, ANKFY1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKFY1 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ANKFY1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKFY1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and PRAD are the cancer types where ANKFY1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	III,IV	0.262	0.838	<.001	12	view →
UCEC	DFS	Median	All	0.918	0.615	.016	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
READ	OS	Median	II,III,IV	0.685	0.933	.003	5	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ANKFY1 tumor-vs-normal RNA expression · all ANKFY1 data types